Cargando…

Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France

The objective of this study was to assess the clinical impact and financial costs of next-generation sequencing (NGS) in 5 categories of pediatric and adult hematological cancers. NGS prescriptions were prospectively collected from 26 laboratories, with varied technical and reporting practice (all o...

Descripción completa

Detalles Bibliográficos
Autores principales: Darlington, Meryl, Sujobert, Pierre, Kosmider, Olivier, Luque Paz, Damien, Kaltenbach, Sophie, Figeac, Martin, Hayette, Sandrine, Mezaour, Nadia, Coquerelle, Séverine, Alary, Anne-Sophie, Bidet, Audrey, Le Bris, Yannick, Delabesse, Eric, Davi, Frédéric, Preudhomme, Claude, Durand-Zaleski, Isabelle, Macintyre, Elizabeth, Alame, Mélissa, Baran-Marzak, Fanny, Berger, Marc G., Bories, Dominique, Caye-Eude, Aurélie, Cayuela, Jean-Michel, Cornillet-Lefebvre, Pascale, Delhommeau, François, Estienne-Felix, Marie-Hélène, Etancelin, Pascaline, Flandrin-Gresta, Pascale, Lippert, Eric, Marzac, Christophe, Miguet, Laurent, Pastoret, Cédric, Raynaud, Sophie, Rizzo, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455455/
https://www.ncbi.nlm.nih.gov/pubmed/37637995
http://dx.doi.org/10.1097/HS9.0000000000000943
_version_ 1785096455163215872
author Darlington, Meryl
Sujobert, Pierre
Kosmider, Olivier
Luque Paz, Damien
Kaltenbach, Sophie
Figeac, Martin
Hayette, Sandrine
Mezaour, Nadia
Coquerelle, Séverine
Alary, Anne-Sophie
Bidet, Audrey
Le Bris, Yannick
Delabesse, Eric
Davi, Frédéric
Preudhomme, Claude
Durand-Zaleski, Isabelle
Macintyre, Elizabeth
Alame, Mélissa
Baran-Marzak, Fanny
Berger, Marc G.
Bories, Dominique
Caye-Eude, Aurélie
Cayuela, Jean-Michel
Cornillet-Lefebvre, Pascale
Delhommeau, François
Estienne-Felix, Marie-Hélène
Etancelin, Pascaline
Flandrin-Gresta, Pascale
Lippert, Eric
Marzac, Christophe
Miguet, Laurent
Pastoret, Cédric
Raynaud, Sophie
Rizzo, David
author_facet Darlington, Meryl
Sujobert, Pierre
Kosmider, Olivier
Luque Paz, Damien
Kaltenbach, Sophie
Figeac, Martin
Hayette, Sandrine
Mezaour, Nadia
Coquerelle, Séverine
Alary, Anne-Sophie
Bidet, Audrey
Le Bris, Yannick
Delabesse, Eric
Davi, Frédéric
Preudhomme, Claude
Durand-Zaleski, Isabelle
Macintyre, Elizabeth
Alame, Mélissa
Baran-Marzak, Fanny
Berger, Marc G.
Bories, Dominique
Caye-Eude, Aurélie
Cayuela, Jean-Michel
Cornillet-Lefebvre, Pascale
Delhommeau, François
Estienne-Felix, Marie-Hélène
Etancelin, Pascaline
Flandrin-Gresta, Pascale
Lippert, Eric
Marzac, Christophe
Miguet, Laurent
Pastoret, Cédric
Raynaud, Sophie
Rizzo, David
author_sort Darlington, Meryl
collection PubMed
description The objective of this study was to assess the clinical impact and financial costs of next-generation sequencing (NGS) in 5 categories of pediatric and adult hematological cancers. NGS prescriptions were prospectively collected from 26 laboratories, with varied technical and reporting practice (all or only significant targets). Impact was defined by the identification of (1) an actionable mutation, (2) a mutation with prognostic and/or theranostic value, and/or (3) a mutation allowing nosological refinement, reported by local investigators. A microcosting study was undertaken in 4 laboratories, identifying the types and volumes of resources required for each procedural step. Individual index prescriptions for 3961 patients were available for impact analysis on the management of myeloid disorders (two thirds) and, mainly mature B, lymphoid disorders (one third). NGS results were considered to impact the management for 73.4% of prescriptions: useful for evaluation of prognostic risk in 34.9% and necessary for treatment adaptation (actionable) in 19.6%, but having no immediate individual therapeutic impact in 18.9%. The average overall cost per sample was 191 € for the restricted mature lymphoid amplicon panel. Capture panel costs varied from 369 € to 513 €. Unit costs varied from 0.5 € to 5.7 € per kb sequenced, from 3.6 € to 11.3 € per target gene/hot-spot sequenced and from 4.3 € to 73.8 € per target gene/hot-spot reported. Comparable costs for the Amplicon panels were 5–8 € per kb and 10.5–14.7 € per target gene/hot-spot sequenced and reported, demonstrating comparable costs with greater informativity/flexibility for capture strategies. Sustainable funding of precision medicine requires a transparent discussion of its impact on care pathways and its financial aspects.
format Online
Article
Text
id pubmed-10455455
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104554552023-08-26 Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France Darlington, Meryl Sujobert, Pierre Kosmider, Olivier Luque Paz, Damien Kaltenbach, Sophie Figeac, Martin Hayette, Sandrine Mezaour, Nadia Coquerelle, Séverine Alary, Anne-Sophie Bidet, Audrey Le Bris, Yannick Delabesse, Eric Davi, Frédéric Preudhomme, Claude Durand-Zaleski, Isabelle Macintyre, Elizabeth Alame, Mélissa Baran-Marzak, Fanny Berger, Marc G. Bories, Dominique Caye-Eude, Aurélie Cayuela, Jean-Michel Cornillet-Lefebvre, Pascale Delhommeau, François Estienne-Felix, Marie-Hélène Etancelin, Pascaline Flandrin-Gresta, Pascale Lippert, Eric Marzac, Christophe Miguet, Laurent Pastoret, Cédric Raynaud, Sophie Rizzo, David Hemasphere Article The objective of this study was to assess the clinical impact and financial costs of next-generation sequencing (NGS) in 5 categories of pediatric and adult hematological cancers. NGS prescriptions were prospectively collected from 26 laboratories, with varied technical and reporting practice (all or only significant targets). Impact was defined by the identification of (1) an actionable mutation, (2) a mutation with prognostic and/or theranostic value, and/or (3) a mutation allowing nosological refinement, reported by local investigators. A microcosting study was undertaken in 4 laboratories, identifying the types and volumes of resources required for each procedural step. Individual index prescriptions for 3961 patients were available for impact analysis on the management of myeloid disorders (two thirds) and, mainly mature B, lymphoid disorders (one third). NGS results were considered to impact the management for 73.4% of prescriptions: useful for evaluation of prognostic risk in 34.9% and necessary for treatment adaptation (actionable) in 19.6%, but having no immediate individual therapeutic impact in 18.9%. The average overall cost per sample was 191 € for the restricted mature lymphoid amplicon panel. Capture panel costs varied from 369 € to 513 €. Unit costs varied from 0.5 € to 5.7 € per kb sequenced, from 3.6 € to 11.3 € per target gene/hot-spot sequenced and from 4.3 € to 73.8 € per target gene/hot-spot reported. Comparable costs for the Amplicon panels were 5–8 € per kb and 10.5–14.7 € per target gene/hot-spot sequenced and reported, demonstrating comparable costs with greater informativity/flexibility for capture strategies. Sustainable funding of precision medicine requires a transparent discussion of its impact on care pathways and its financial aspects. Lippincott Williams & Wilkins 2023-08-24 /pmc/articles/PMC10455455/ /pubmed/37637995 http://dx.doi.org/10.1097/HS9.0000000000000943 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Darlington, Meryl
Sujobert, Pierre
Kosmider, Olivier
Luque Paz, Damien
Kaltenbach, Sophie
Figeac, Martin
Hayette, Sandrine
Mezaour, Nadia
Coquerelle, Séverine
Alary, Anne-Sophie
Bidet, Audrey
Le Bris, Yannick
Delabesse, Eric
Davi, Frédéric
Preudhomme, Claude
Durand-Zaleski, Isabelle
Macintyre, Elizabeth
Alame, Mélissa
Baran-Marzak, Fanny
Berger, Marc G.
Bories, Dominique
Caye-Eude, Aurélie
Cayuela, Jean-Michel
Cornillet-Lefebvre, Pascale
Delhommeau, François
Estienne-Felix, Marie-Hélène
Etancelin, Pascaline
Flandrin-Gresta, Pascale
Lippert, Eric
Marzac, Christophe
Miguet, Laurent
Pastoret, Cédric
Raynaud, Sophie
Rizzo, David
Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France
title Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France
title_full Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France
title_fullStr Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France
title_full_unstemmed Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France
title_short Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France
title_sort targeted high-throughput sequencing for hematological malignancies: a gbmhm survey of practice and cost evaluation in france
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455455/
https://www.ncbi.nlm.nih.gov/pubmed/37637995
http://dx.doi.org/10.1097/HS9.0000000000000943
work_keys_str_mv AT darlingtonmeryl targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT sujobertpierre targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT kosmiderolivier targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT luquepazdamien targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT kaltenbachsophie targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT figeacmartin targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT hayettesandrine targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT mezaournadia targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT coquerelleseverine targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT alaryannesophie targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT bidetaudrey targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT lebrisyannick targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT delabesseeric targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT davifrederic targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT preudhommeclaude targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT durandzaleskiisabelle targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT macintyreelizabeth targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT alamemelissa targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT baranmarzakfanny targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT bergermarcg targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT boriesdominique targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT cayeeudeaurelie targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT cayuelajeanmichel targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT cornilletlefebvrepascale targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT delhommeaufrancois targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT estiennefelixmariehelene targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT etancelinpascaline targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT flandringrestapascale targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT lipperteric targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT marzacchristophe targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT miguetlaurent targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT pastoretcedric targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT raynaudsophie targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance
AT rizzodavid targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance